¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"ligand binding site"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ligand binding site
    ¸®°£µå°áÇÕºÎÀ§
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • binding site
    °áÇÕºÎÀ§
  • receptor-ligand interaction
    ¼ö¿ëü¸®°£µå»óÈ£ÀÛ¿ë
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • combining site
    °áÇÕºÎÀ§
  • donor site
    Á¦°øºÎÀ§, °ø¿©ºÎÀ§
  • fragile site
    Ãë¾àºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • site
    ºÎÀ§
  • telomeric site
    ³¡ºÐÀýºÎÀ§
  • antigen binding capacity
    Ç׿ø°áÇÕ´É
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • site
    ºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • binding
    ¹­À½, °áÇÕ
  • protein binding
    ´Ü¹é°áÇÕ
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • total iron binding capacity
    ÃÑö°áÇÕ´É
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • binding site
    °áÇÕºÎÀ§
  • receptor-ligand interaction
    ¼ö¿ëü¹èÀ§ÀÚ»óÈ£ÀÛ¿ë
  • absorption site
    Èí¼öºÎÀ§
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • combining site
    °áÇÕºÎÀ§
  • definitive site
    Âø»óºÎÀ§
  • donor site
    ÁִºÎÀ§, Á¦°øºÎÀ§
  • mutational site
    µ¹¿¬º¯À̺ÎÀ§
  • packaging site
    ²Ù¸®±âºÎÀ§
  • privileged site
    Ưº°°Ý¸®ºÎÀ§
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • Ligand-gated channels
    ¸®°£µå°ü¹®(¡­Î¼Ú¦) ÀÌ¿ÂÅë·Î(¡­÷×ÖØ)
  • receptor-ligand interaction
    ¼ö¿ëü-¹èÀ§ÀÚ »óÈ£ÀÛ¿ë
  • absorption site
    Èí¼öÁ¡
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ºÀÚ¸®.
  • antibody combining site
    Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
  • antigen combining site
    Ç׿ø°áÇպΠ(¡­Ì¿ùêÝ»).
  • antigen recognition site
    Ç׿ø½Äº°ºÎ.
  • fundic site
    ÀڱùٴÚÀÓ½Å
  • placental site trophoblastic tumor
    ŹݺÎÂøºÎÀ§ À¶¸ð»óÇǼºÁ¾¾ç
  • privileged site
    Ưº°°Ý¸®ºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§.
  • ABP=> androgen-binding protein
    ¾Èµå·ÎÁ¨°áÇմܹé
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cell growth,ligand receptor binding
    ¸®°£µå¼ö¿ë±â°áÇÕ (¡­áôé»ÐïÌ¿ùê)
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • binding site
    °áÇÕºÎÀ§.
  • binding site
    °á ÇÕºÎÀ§.
  • ligand
    ¹èÀ§ÀÚ, ¸®°£µå
  • receptor-ligand interaction
    ¼ö¿ëü-¹èÀ§ÀÚ »óÈ£ÀÛ¿ë
  • absorption site
    Èí¼öÁ¡
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ºÀÚ¸®.
  • antibody combining site
    Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
  • antigen combining site
    Ç׿ø°áÇպΠ(¡­Ì¿ùêÝ»).
  • antigen recognition site
    Ç׿ø½Äº°ºÎ.
  • combining site
    °áÇÕºÎ(Ì¿ùêÝ»).
  • combining site
    °áÇÕºÎÀ§
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Variations of site
    À§Ä¡º¯ÀÌ
    [¿¾ ¿ë¾î] À§Ä¡ÀÌ»ó
  • Corporal site
    ÀڱøöÅëÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃüºÎ
  • Absorption site
    Èí¼öÁ¡
    [¿¾ ¿ë¾î] Èí¼öÃÊÁ¡
  • Fundic site
    ÀڱùٴÚÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃÀúºÎ
  • Definitive site
    Âø»óÀÚ¸®
    [¿¾ ¿ë¾î] À§Ä¡¼±Á¤
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen binding site
    Ç׿ø°áÇÕ(ù÷ê«Ì¿ùê)ÀÚ¸®
  • binding site
    °áÇÕ(Ì¿ùê)ÀÚ¸®
  • excluded site binding
    ¹èÁ¦(ÛÉð¶)ÀÚ¸® °áÇÕ(Ì¿ùê)
  • ribosome binding site
    ¶óÀ̺¸¼Ø °áÇÕ(Ì¿ùê)ÀÚ¸®
  • substrate-binding site
    ±âÁú°áÇÕ (ÐñòõÌ¿ùê) ÀÚ¸®
  • A-site-P-site moel
    AÀÚ¸® PÀÚ¸® ¸ðµ¨
  • hard ligand
    °æ(Ìã)¶óÀ̰£µå
  • ligand
    ¸®°£µå
  • ligand chromatography
    ¸®°£µå Å©·Î¸¶Åä±×·¡ÇÇ
  • ligand-exchange chromatography
    ¸®°£µå±³È¯(Îßüµ) Å©·Î¸¶Åä±×¶óÇÇ
  • ligand field theory
    ¸®°£µåÀå(íÞ) ÀÌ·Ð(ìµÖå)
  • ligand-gated channel
    ¸®°£µå °ü¹®Åë·Î(μڦ÷×ÖØ)
  • ligand-induced endocytosis
    ¸®°£µåÀ¯µµ(ë¯Óô) ¼¼Æ÷³»À¯ÀÔ(á¬øàÒ®×µìý)
  • ligand-receptor internalization
    ¸®°£µå-¼ö¿ëü(áôé»ô÷) ³»ÀÔ(Ò®ìý)
  • monodentate ligand
    ÇÑÀÚ¸®¸®°£µå
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • binding
    ¹­À½, °áÇÕ
  • binding energy
    °áÇÕ¿¡³ÊÁö
  • site
    À§Ä¡,»çÀÌÆ®
  • web site
    À¥½ÎÀÌÆ®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
FS factor of safety; Fanconi syndrome; Felty syndrome; fibromyalgia syndrome; field stimulation; Fisher...
ABP actin-binding protein; ambulatory blood pressure; American Board of Pedodontics; American Board of P...
CBP calcium-binding protein; carbohydrate-binding protein; cardiopulmonary bypass; chlorobiphenyl; cobal...
TBG beta-thromboglobulin; testosterone-binding globulin; thyroglobulin; thyroid-binding globulin; thyrox...
CLD chloride diarrhea; chronic liver disease; chronic lung disease; congenital limb deficiency; crystal ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Site 1 site
LBA Ligand Binding Assay
LIBS Ligand-induced binding sites
LBD ligand binding domain
DBP D site binding protein
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ligand receptor binding
    ¸®°£µå ¼ö¿ë±â °áÇÕ
  • antigen binding site
    Ç׿ø °áÇÕ ºÎÀ§
    ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 3Â÷ ±¸Á¶»ó H ¼â¿Í L ¼âÀÇ °¡º¯¿µ¿ª¿¡¼­ ±¸¼ºµÇ¾î ÀÖ´Â Ç׿ø°ú °áÇÕÇÏ´Â ºÎÀ§.
  • endogenous ligand
    ³»Àμº ¹èÀ§ÀÚ
  • alpha 2 binding
    ¾ËÆÄ 2 °áÇÕ
  • androgen binding protein
    ³²¼º È£¸£¸ó °áÇÕ ´Ü¹é
  • antigen binding cell
    Ç׿ø °áÇÕ ¼¼Æ÷
    Ç׿ø¿¡ ´ëÇÑ Æ¯ÀÌÀûÀÎ °áÇձ⸦ ¼¼Æ÷ Ç¥¸é¿¡ °¡Áö°í ÀÖÀ¸¸ç Ç׿øÀ» ¼¼Æ÷ Ç¥¸é¿¡ °áÇÕ½ÃŰ´Â ´É·ÂÀ» °¡Áø ¼¼Æ÷. B ¼¼Æ÷ ¹× ÀϺÎÀÇ T ¼¼Æ÷°¡ Ç׿ø °áÇÕ ¼¼Æ÷¿¡ ÇØ´çµÈ´Ù. À̵éÀÇ ¸²ÇÁ±¸ÀÇ ¼¼Æ÷ Ç¥¸é¿¡ Ç׿øÀÌ °áÇյǾî ÀÖ´Â »óŸ¦ °¢Á¾ ¹æ¹ýÀ¸·Î È®ÀÎÇÒ ¼ö ÀÖ´Ù. Ç׿øÀ» ¹æ»ç¼º ¹°Áú·Î Ç¥ÁöÇØ µÎ°í autoradiogra
  • antigen binding fragment
    Ç׿ø °áÇÕ ºÎÀ§
  • antigen combining site
    Ç׿ø °áÇÕºÎ
  • antigen recognition site
    Ç׿ø ½Äº°ºÎ
  • binding activity
    °áÇÕ È°¼º
  • binding displacement analysis
    °áÇÕ º¯À§ ºÐ¼®
  • binding orbit
    °áÇÕ ±Ëµµ
  • cellular retinoid acid-binding protein
    ¼¼Æ÷³» ·¹Æ¼³ëÀ̵å»ê °áÇÕ ´Ü¹é
  • cleavage site
    ºÐ¿­ ºÎÀ§
  • combining site
    °áÇÕºÎ
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
ligand binding site The site on a protein's surface that binds a ligand; equivalent to the active site if the ligand is the substrate of an enzyme.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
ribosome binding site The region of a messenger RNA molecule that binds the ribosome to initiate translation.
(09 Oct 1997)
Con A binding site <biochemistry> A common misuse of the term receptor. Con A binds to the mannose residues of many different glycoproteins and glycolipids and the binding is therefore not to a specific site.
It could be argued that the receptor is the Con A and cells have Con A ligands on their surfaces: certainly this would be less confusing.
(05 Jan 1998)
ambident ligand <chemistry> A ligand that can donate electrons through two or more atoms on their molecule.
(05 Feb 1998)
cyanocobalamin beta-ligand transferase <enzyme> Cytosolic enzyme utilizing fad, NADPH and reduced glutathione; forms glutathionylcobalamin from cyanocobalamin
Registry number: EC 2.5.1.-
Synonym: ccbl transferase
(26 Jun 1999)
ELAM-1 ligand fucosyltransferase <enzyme> Directs the expression of an elam-1 ligand; an alpha(1,3) fucosyltransferase
Registry number: EC 2.4.1.-
Synonym: elft protein, elft gene product
(26 Jun 1999)
ligand <chemistry, immunology> Any molecule that binds to another, in normal usage a soluble molecule such as a hormone or neurotransmitter, that binds to a receptor. The decision as to which is the ligand and which the receptor is often a little arbitrary when the broader sense of receptor is used (where there is no implication of transduction of signal). In these cases it is probably a good rule to consider the ligand to be the smaller of the two thus in a lectin sugar interaction, the sugar would be the ligand (even though it is attached to a much larger molecule, recognition is of the saccharide).
(18 Nov 1997)
ligand-gated channel A class of ion channel's whose ionic permeability is regulated by cell membrane receptors that respond to specific extracellular chemical signals.
(05 Mar 2000)
ligand gated ion channel A transmembrane ion channel whose permeability is increased by the binding of a specific ligand, typically a neurotransmitter at a chemical synapse. The permeability change is often drastic, such channels let through effectively no ions when shut, but allow passage at up to 10exp7 ions sexp 1 when a ligand is bound. Recently, the receptors for both acetylcholine and GABA have been found to share considerable sequence homology, implying that there may be a family of structurally related ligand gated ion channels.
(18 Nov 1997)
ligand induced endocytosis The formation of coated pits and then coated vesicles as a consequence of the interaction of ligand with receptors, which then interact with clathrin and associated proteins (coatomers) on the cytoplasmic face of the plasma membrane and come together to form a pit. Not all coated vesicle uptake of receptors requires receptor occupancy.
(18 Nov 1997)
acceptor site The ribosomal binding site for the aminoacyl-tRNA during protein synthesis.
(05 Mar 2000)
acceptor splicing site Boundary between the right end of an intron and the left end of the adjacent exon.
Synonym: acceptor splicing site.
(05 Mar 2000)
active site <chemistry> A specific region of an enzyme where a substrate binds and catalysis takes place (binding site).
(06 May 1997)
allosteric site A specific site on a multi-subunit enzyme or other protein that is not the substrate binding site, but that when reversibly bound by an effector, induces a conformational change in the protein, altering its catalytic or binding properties.
(12 Dec 1998)
amidation site <molecular biology> A C terminus consensus sequence, required for C terminus amidation of peptides. Consensus is glycine, followed by 2 basic amino acids (arg or lys).
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • site
    À§Ä¡
  • caravan park (site)
    À̵¿ÁÖÅÃ(Æ®·¹ÀÏ·¯) ÁÖÂ÷Àå
  • ceru(s)site
    ¹é¿¬±¤
  • county seat (site)
    ±ºÃ» ¼ÒÀçÁö;±ºÀÇÇàÁ¤ Áß½ÉÁö
  • launching site
    ¹ß»ç±âÁö
  • receptor site
    ¼¼Æ÷³» ¼ö¿ë ¿µ¿ª
  • restriction site
    Á¦ÇÑ ºÎÀ§(Á¦ÇÑ È¿¼Ò°¡ Àý´ÜÇÏ´Â µÎ ÁÙ »ç½½ DNA»óÀÇ ºÎÀ§)
  • site
    À§Ä¡;Àå¼Ò;¿ëÁö;ºÎÁö !
  • binding
    Á¦º»
  • Grolier binding(design)
    ±×·Ñ¸®¾î½Ä ÀåÁ¤(µðÀÚÀÎ)(±×´Â ±Ý½Ç·Î ¿«¾î ¸¸µç Àå½Ä)
  • binding
    ¹­´Â;µ¿ÀÌ´Â;Á¦º»;ºØ´ë;¼Ó¹Ú;¼Ó¹ÚÇÏ´Â
  • binding energy
    °áÇÕ¿¡³ÊÁö
  • cloth binding
    (Ã¥ÀÇ)Ŭ·Î½ºÇ¥Áö(Á¦º»);Ŭ·Î½ºÀåÁ¤(º»)
  • edition binding
    (Á¦º»)¹ÌÀå Á¦º»(Àå½ÄÀû üÁ¦¸¦ Áß¿ä½ÃÇÔ)
  • full binding
    ÃÑÇÇ Á¦º»
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á